Johnson & Johnson has reached a deal to acquire Shockwave Medical for around $ ... in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney ...

especially following the Shockwave Medical acquisition completed in May of last year. With a market capitalization of $363 billion, Johnson & Johnson generated $89 billion in revenue over the past ...

Johnson & Johnson was the first biopharmaceutical ... The company grew through the acquisition of Abiomed (approximately $17 billion) and Shockwave (approximately $13 billion).